Maria Gutierrez-Larrañaga

Mrs. Maria Gutierrez-Larrañaga


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
ÁSÁlvaro Santos-Laso
Álvaro Santos-Laso
MGMaria Gutierrez-Larrañaga
Maria Gutierrez-Larrañaga
MAMarta Alonso-Peña
Marta Alonso-Peña
JMJuan M. Medina
Juan M. Medina
PIPAULA IRUZUBIETA
PAULA IRUZUBIETA
JCJavier Crespo
Javier Crespo
Non-alcoholic fatty liver disease (NAFLD) is characterized by the excessive and detrimental accumulation of liver fat as a result of high-caloric intake and/or cellular and molecular abnormalities. The prevalence of this pathological event is increasing worldwide, and is intimately associated with obesity and type 2 diabetes mellitus, among other comorbidities. To date, only therapeutic strategies based on lifestyle changes have exhibited a beneficial impact on patients with NAFLD, but unfortunately this approach is often difficult to implement, and shows poor long-term adherence. For this reason, great efforts are being made to elucidate and integrate the underlying pathological molecular mechanism, and to identify novel and promising druggable targets for therapy. In this regard, a large number of clinical trials testing different potential compounds have been performed, albeit with no conclusive results yet. Importantly, many other clinical trials are currently underway with results expected in the near future. Here, we summarize the key aspects of NAFLD pathogenesis and therapeutic targets in this frequent disorder, highlighting the most recent advances in the field and future research directions.

15 July 2020 in Transplantology
Verified
Journal Article
Open access
PDF file
MGMaria Gutierrez-Larrañaga
Maria Gutierrez-Larrañaga
Marcos Lopez-HoyosMarcos Lopez-Hoyos
Marcos Lopez-Hoyos
ARAndre Renaldo
Andre Renaldo
DSDavid San Segundo
David San Segundo
The role of anti-HLA antibodies in solid organ rejection is well established and these antibodies are routinely monitored both in patients in the waiting list and in the post-transplant setting. More recently, the presence of other antibodies directed towards non-HLA antigens, or the so-called minor histocompatibility antigens, has drawn the attention of the transplant community; however, their possible involvement in the graft outcome remains uncertain. These antibodies have been described to possibly have a role in rejection and allograft failure. This review focuses on the most studied non-HLA antibodies and their association with different clinical outcomes considered in solid organ transplantation with the aim of clarifying their clinical implication and potential relevance for routine testing.

22 July 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
DSDavid San Segundo
David San Segundo
ACAlejandra Comins-Boo
Alejandra Comins-Boo
JIJuan Irure-Ventura
Juan Irure-Ventura
MRMónica Renuncio-García
Mónica Renuncio-García
ARAdriel Roa-Bautista
Adriel Roa-Bautista
Marcos Lopez-HoyosMarcos Lopez-Hoyos
Marcos Lopez-Hoyos
Vaccine efficacy is based on clinical data. Currently, the assessment of immune response after SARS-CoV-2 vaccination is scarce. A total of 52 healthcare workers were immunized with the same lot of BNT162b2 vaccine. The immunological response against the vaccine was tested using a T-specific assay based on the expression of CD25 and CD134 after stimulation with anti-N, -S, and -M specific peptides of SARS-CoV-2. Moreover, IgG anti-S2 and -RBD antibodies were detected using ELISA. Furthermore, the cell subsets involved in the response to the vaccine were measured in peripheral blood by flow cytometry. Humoral-specific responses against the vaccine were detected in 94% and 100% after the first and second doses, respectively. Therefore, anti-S T-specific responses were observed in 57% and 90% of the subjects after the first and second doses of the vaccine, respectively. Thirty days after the second dose, significant increases in T helper 1 memory cells (p < 0.001), peripheral memory T follicular helper (pTFH) cells (p < 0.032), and switched memory (p = 0.005) were observed. This study describes the specific humoral and cellular immune responses after vaccination with the new mRNA-based BNT162b2 vaccine. A mobilization of TFH into the circulation occurs, reflecting a specific activation of the immune system.